pantoprazole has been researched along with Osteosarcoma in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fox, E | 1 |
| Levin, K | 1 |
| Zhu, Y | 1 |
| Segers, B | 1 |
| Balamuth, N | 1 |
| Womer, R | 1 |
| Bagatell, R | 1 |
| Balis, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma[NCT01848457] | Phase 2 | 13 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum BSAP will be longitudinally evaluated as a potential biomarker for osteosarcoma (NCT01848457)
Timeframe: Pretreatment/Baseline, Cycle 3
| Intervention | U/L (Mean) | |
|---|---|---|
| Pretreatment (baseline) | Cycle 3 | |
| Arm 1 | 197.1 | 73.05 |
| Arm 2 | 265 | 106.87 |
| Arm 3 | 169.67 | 71.2 |
| Arm 4 | 179.63 | 76.1 |
Response of the primary tumor to the first two treatment cycles (Cycles 1 and 2) will be assessed by quantifying the change in tumor volume on MRI, after treatment (pre-operative) relative to the pre-treatment tumor volume. By using the log ratio of the tumor volume post-treatment, to the tumor volume pre-treatment. The larger the change, the more effective the treatment. (NCT01848457)
Timeframe: Baseline (Week 1), Pre-operative (Month 2)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete Response to Chemotherapy | Progressive Disease after Chemotherapy | |
| Localized Disease at Baseline | 9 | 0 |
| Metastatic Disease at Baseline | 0 | 4 |
"This measure describes the urinary biomarkers of AKI after each course of C throughout Cycles 1-2, compared to baseline (pre-infusion) values.~Biomarkers of AKI, include: Kidney Injury Molecule-1 (KIM-1), and Neutrophil Gelatinase-Associated Lipocalin (NGAL)." (NCT01848457)
Timeframe: Pretreatment/Baseline, Day 2 of Cycles 1 & 2, Day 8 of Cycles 1 & 2
| Intervention | μg/g (Median) | |||||
|---|---|---|---|---|---|---|
| Day 1 Kim-1 (Pretreatment) | Day 2 Kim-1 (post 2 doses Cisplatin) | Day 8 Kim-1 (post HDTMX infusion) | Day 1 NGAL (Pretreatment) | Day 2 NGAL (post 2 doses Cisplatin) | Day 8 NGAL (post HDTMX infusion) | |
| Treatments Arms 1 & 3 (Groups With PTZ in Cycles 1 & 2) | 1.7 | 2.1 | 4.1 | 18 | 27 | 12 |
| Treatments Arms 2 & 4 (Groups Without PTZ in Cycles 1 & 2) | 1.7 | 3.3 | 4.6 | 10 | 18 | 12 |
Average hearing level (HL) threshold in decibels (dB) over the frequency range of 4,000-8,000 hertz (Hz) will be derived separately for each ear from audiograms performed before each dose of cisplatin. (NCT01848457)
Timeframe: Baseline (Week 1), Day 1 of Cycle 1 (Week 1), Day 1 of Cycle 2(Week 6), Day 1 of Cycle 3(Week 11), Day 1 of Cycle 4 (Week 16), and end of therapy/after the end of cycle 6 (Day 28 of cycle 6, Week 28)
| Intervention | decibels (Mean) | |||
|---|---|---|---|---|
| Baseline Right Ear | Baseline Left Ear | End of Therapy Right Ear | End of Therapy Left Ear | |
| Treatment Arms 1, 3 (w/ Pantoprazole) | 3.6 | 3.3 | 34.6 | 35.0 |
| Treatment Arms 2, 4 (w/o Pantoprazole) | 3.8 | 5.4 | 26.7 | 26.7 |
PROS survey measures quality of life for pediatric oncology patients, in 17 scaled questions. Each question scaled 0-4 (0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Often, 4 = Almost Always). The higher the final sum of the questions, the lower the quality of life/more severe the side effects of oncology treatment. Total scores can range between 0 = highest quality of life, and 100 = experiencing most severe side effects of oncology treatment/worst quality of life experience. (NCT01848457)
Timeframe: Baseline, Cycle 2, Surgery, Cycle 3, Cycle 4, Cycle 5, Cycle 6, and End of Therapy
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Cycle 2 | Surgery | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | End of Therapy | |
| All Study Participants (Arms 1-4) | 23 | 30 | 22 | 24 | 24 | 19 | 20 | 17 |
Urinary biomarkers of acute kidney injury (AKI) and glomerular filtration rate (GFR) estimated from serum cystatin C will be compared to standard measures of renal function (serum creatinine, urinalysis, estimated creatinine clearance, fractional excretion of Mg). Single reported values are averaged and reported with full ranges. (NCT01848457)
Timeframe: Day 1 (Pretreatment/Baseline), Day 8, and Day 22 of Cycles 1 & 2
| Intervention | mL/min per 1.73m2 (Median) | |||||
|---|---|---|---|---|---|---|
| Day 1 GFRcr (pretreatment) | Day 8 GFRcr | Day 22 GFRcr | Day 1 GFRcysC (pretreatment) | Day 8 GFRcysC | Day 22 GFRcysC | |
| Treatment Arms 1, 3 (w/ Pantoprazole) | 131 | 120 | 134 | 126 | 105 | 122 |
| Treatment Arms 2, 4 (w/o Pantoprazole) | 132 | 124 | 141 | 120 | 109 | 125 |
1 trial available for pantoprazole and Osteosarcoma
| Article | Year |
|---|---|
Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2018 |